Dr. David Steensma on Myelodysplastic Syndrome

Video

In Partnership With:

David P. Steensma, MD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute discusses myelodysplastic syndromes.

David P. Steensma, MD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute discusses myelodysplastic syndromes.

Myelodysplastic syndromes are increasingly recognized, with 30,000-35,000 new cases per year in the United States. These are both marrow failure syndromes and bone marrow cancers, as the majority of patients have either a chromosome abnormality or systemic genetic mutation or both, explains Steensma. There is a risk that myelodysplastic syndromes will progress to acute leukemia.

Individualized therapy is currently based on risk stratification and clinical pathological disease features, said Steensma. However, in the future molecular genetic profiling will play an increasing role.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD